Snoop Dogg-Backed Cannabis Biotech Joins Forces With Former Google Experts To Boost AI Drug Discovery
London-headquartered Oxford Cannabinoid Technologies confirmed Tuesday the successful completion of proof of concept of its AI-enabled drug discovery asset, which it is developing in collaboration with New York-based tech consultancy, Hypatia AI. The Snoop Dogg-backed cannabis biotech launched in 2017 and has been collaborating with Oxford University, mainly focusing on the development of pain-relieving, cannabinoid-based medications.
Hypatia is designing an AI tool to speed up OCT’s drug discovery process. The tool gathers insights from extensive scientific literature, allowing OCT’s team more time for research analysis. This focused approach helps researchers find connections and insights that might otherwise be overlooked. By amplifying OCT’s expertise, the tool enables the team to explore groundbreaking possibilities for developing non-addictive, cannabinoid-based pain medications, reducing opioid reliance faster than ever before.
“I am very pleased to announce the successful development of this innovative asset that will fuel OCT’s future work and journey,” stated Clarissa Sowemimo-Coker, chief executive officer of OCT. “We’ve been working closely with David Gordon‘s team at Hypatia …